Plus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights (GlobeNewswire) - Feb 24, 2022 - "The Company's near- and mid-term business objectives include the following: Recurrent GBM: (i) Initiate a Phase 2 clinical trial in patients with recurrent GBM; (ii) Complete FDA CMC and clinical meetings for the ReSPECT-GBM program; (iii) Complete CMC activities for 186RNL for GMP Phase 2 drug supply; (iv) Continue ReSPECT-GBM Phase 1 trial of 186RNL, dose escalation and report data; (v) Initiate ReSPECT-GBM retreatment protocol following FDA approval."
Commercial • FDA event • New P2 trial • P1 data • Trial status • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
|